Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 7, 2024) - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developments for the treatment of viruses, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/06070Virus-Treatment ...

Aethlon Medical (NASDAQ:AEMD) stock is soaring higher on Thursday alongside strong pre-market trading for the medical therapeutic company’s shares. Aethlon Medical is experiencing heavy trading today with more than 26 million shares exchanging hands as of this writing. That’s a massive increase over its daily average trading volume of about 974,000 shares. It’s also worth noting that the company’s float is roughly 2.56 million shares. This heavy trading comes despite a lack of news from Aethlon Medical. Tha ...

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 3, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at medical device advancements for blood purification, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases. Read the full article on Investorideas.com https://www.investorideas.com/News/2024/biotech/06030Blood-Purificati ...

SAN DIEGO, May 15, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the pricing of a public offering of an aggregate of 8,100,000 shares of its common stock (or pre- funded warrants in lieu thereof), Class A warrants to purchase up to 8,100,000 shares of common stock, and Class B warrants to purchase up to 8,100,000 shares of common stock, at a combined public offe ...

Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of the Hemopurifier In Cancer Patients With Solid Tumors Treated With Anti-PD-1 Antibodies SAN DIEGO, May 10, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced positive results from an in vitro binding study of its Hemopurifier® in removing extracellular vesicles (EVs) from p ...

Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Filtration System SAN DIEGO, Feb. 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it entered into a Materials Transfer Agreement (MTA) with Santersus AG, a Zurich-London based, privately held therapeutic medical device company, for ...

财务数据和关键指标变化 - 截至2023年12月31日,公司现金余额约为800万美元 [14] - 2023年12月和1月,公司通过ATM计划筹集了约23.6万美元 [14] - 2023年12月31日三个月的合并经营费用约为360万美元,较2022年同期增加25.2% [15] - 人工费用增加87.1万美元,主要由于前CEO离职费用873,000美元和平均员工人数增加导致工资费用增加81,000美元 [16] - 一次性离职费用873,000美元被剔除后,人工费用和整体经营费用实际下降 [16][17] - 一般管理费用下降9.2万美元,主要由于临床试验费用减少39.9万美元,但被制造和研发耗材增加28.4万美元和保险费用增加3.1万美元所抵消 [17] - 专业费用下降6.1万美元,主要由于科学咨询费用减少5.4万美元、营销费用减少2.2万美元、招聘费用减少2.1万美元等 [18] - 2023年12月31日三个月的净亏损增加至360万美元,较2022年同期的280万美元增加 [19] 各条业务线数据和关键指标变化 - 公司目前正在进行的是肿瘤和新冠肺炎两个领域的临床试验 [6][8] - 肿瘤领域的临床试验计划在印度和澳大利亚开展,目前正在等待体外结合实验数据 [6][7][11][12] - 新冠肺炎临床试验在印度两家医院进行,目前已有1例患者接受治疗,但由于新变异株导致重症患者较少,受试者入组受限 [8][24][37] 各个市场数据和关键指标变化 - 公司正在印度和澳大利亚开展临床试验,尚未有具体市场数据和指标变化 公司战略和发展方向及行业竞争 - 公司目前将重点放在肿瘤领域的临床试验,并正在减少开支 [9] - 公司还计划发表器官移植领域的研究成果 [9] - 公司正在与第三方实验室合作,对体外实验数据进行独立验证,以支持临床试验设计 [7] 管理层对经营环境和未来前景的评论 - 公司正在推进肿瘤和新冠肺炎临床试验,但新冠肺炎试验受新变异株影响,重症患者较少 [24][37] - 公司正在努力完成体外实验数据的验证,以推进肿瘤临床试验 [7][11][12] - 公司已经为肿瘤临床试验做好了各项准备工作,一旦完成体外实验数据验证就可以启动 [11][12] - 公司正在努力控制开支,并计划发表器官移植领域的研究成果 [9] 问答环节重要的提问和回答 问题1 **Marla Marin 提问** 如果印度新冠肺炎病例增加,是否会有利于公司试验的患者入组? [22] **Steven LaRosa 回答** 公司的试验针对重症患者,如果重症病例增加,公司就有机会入组更多患者。公司在印度已有Hemopurifier设备和医生团队待命,只要有重症患者就可以开始治疗 [24][25][26] 问题2 **Anthony Vendetti 提问** 公司目前是否有足够的Hemopurifier设备支持所有计划中的临床试验? [27] **James Frakes 回答** 对于计划中的肿瘤试验,公司目前有足够的Hemopurifier设备。如果新冠疫情出现大规模爆发,可能会存在设备不足的风险,但目前公司在印度已有备用设备 [28] 问题3 **Anthony Vendetti 提问** 公司是否还有其他一次性费用会在第四季度发生? [29] **James Frakes 回答** 没有,之前计提的前CEO离职费用873,000美元已全部在第三季度入账,未来只需要分期支付该笔费用 [30]

Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2023 and provided an update on recent developments. Company Updates Aethlon Medical is continuing the research and clinical development of its Hemopurifier®, a therapeutic blood filtra ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to_____ COMMISSION FILE NUMBER 001-37487 Aethlon Medical, Inc. (Exact name of registrant as specified in its charter) NEVADA 13-3632859 (State or othe ...

Hemopurifier产品及临床试验 - A 公司是一家专注于开发治疗癌症和危及生命传染病产品的医疗治疗公司[62] - Hemopurifier被FDA指定为两个独立适应症的“突破性设备”[62] - 与NAMSA签订协议，管理Hemopurifier在美国和澳大利亚的临床试验[64] - Hemopurifier在治疗癌症和危及生命的病毒感染方面具有潜在优势[63] - Hemopurifier已在小规模或早期可行性人体研究中用于治疗HIV、丙型肝炎和埃博拉[65] - 在体外实验中，Hemopurifier已被证明可以捕获多种病毒[66] Hemopurifier在印度的发展 - A 公司已在印度成立全资子公司，专注于在该国进行临床研究和商业化Hemopurifier[70] - A 公司已获得印度药品总监的批准，进行Hemopurifier在患有稳定或进展性疾病的实体瘤患者中的安全性、可行性和剂量确定试验[73] 财务状况 - A 公司的净损失从2022年9月30日的380万7430美元降至2023年9月30日的303万6891美元[83] - A 公司截至2023年9月30日的现金余额为1017.59万美元，预计足以支持至少12个月的运营[91] - 公司在2023年9月份的运营活动中使用了约5187,000美元的现金，相比2022年同期的5607,000美元有所减少[98] - 公司在2023年9月份的投资活动中使用了约237,000美元的现金，相比2022年同期的780,000美元有所减少[99] - 公司在2023年9月份的融资活动中筹集了约1,086,000美元的现金，主要来源于发行普通股[100] - 公司预计未来的资本需求将取决于多个因素，包括临床试验费用的增加，专利权的准备、申请、维护和执行成本，以及融资需求[103]